Combination endocrine therapy in the management of breast cancer

Oncologist

Volumn 6, Issue 6, 2001, Pages 538-546

  Michaud, Laura Boehnke ^a   Jones, Kellie L ^a   Buzdar, Aman U ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antiestrogens; Aromatase inhibitors; Breast cancer; Endocrine therapy; LHRH agonists

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BUSERELIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FADROZOLE; FLUOROURACIL; FORMESTANE; FULVESTRANT; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LETROZOLE; METHOTREXATE; TAMOXIFEN; TRIPTORELIN; VOROZOLE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; ESTROGEN ACTIVITY; ESTROGEN SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; TOXICITY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE;

EID: 0035217450     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-6-538     Document Type: Article

References (40)

1. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate
2. Treatment of metastatic breast cancer
3. Effect of CGS 16949A and tamoxifen on DMBA-induced mammary tumors in rats
4. Inhibition of estrogen biosynthesis and regression of mammary tumors by aromatase inhibitors
5. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat
6. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats
7. The effect of combining aromatase inhibitors with antiestrogens on tumor grown in a nude mouse model for breast cancer
8. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide
9. The effect of anastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer
10. Pharmacokinetics of 'Arimidex' and tamoxifen alone and in combination in the ATAC adjuvant breast cancer trial
11. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer
12. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
13. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer
14. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients
15. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer
16. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study
17. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer
18. Combined use of goserelin (Zoladex) and anastrozole (Arimidex) in premenopausal women with metastatic breast cancer (MBC)
19. Changes in serum estrogen levels in women during tamoxifen therapy
20. Clinical breast cancer, new developments in selection and endocrine treatment of patients
21. Long-term peptide hormone treatment with LHRH agonists in metastatic breast cancer
22. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer
23. Endocrine effects of combination antioestrogen and LHRH agonist therapy in premenopausal patients with advanced breast cancer
24. Zoladex plus tamoxifen versus Zoladex alone in pre- and perimenopausal metastatic breast cancer
25. LHRH-agonist treatment in clinical and experimental human breast cancer
26. Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments
27. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (buserelin) with or without tamoxifen in premenopausal metastatic breast cancer
28. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
29. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer: A 5-year experience and further endocrine therapies
30. Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: A multicentre study by the ITMO group
31. Combined goserelin and tamoxifen in premenopausal advanced breast cancer: Duration of response and survival
32. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer
33. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study
34. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
35. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, The South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.I.V.I.O)
36. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial
37. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG)
38. Polychemotherapy for early breast cancer: An overview of the randomised trials
39. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptor positive breast cancer patients; a randomized trial with 7 years median follow up
40. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101)